Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

Movement Disorders

Volumn 20, Issue 5, 2005, Pages 523-539

  Goetz, Christopher G ^a   Poewe, Werner ^b   Rascol, Olivier ^c   Sampaio, Cristina ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Amantadine; Anticholinergics; COMT inhibitors; Deep brain stimulation; Dopamine agonist; Evidence based medicine; Levodopa; Monoamine oxidase inhibitors; Neurosurgery; Neurotransplantation; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROERGOCRYPTINE; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ABDOMINAL PAIN; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSKINESIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; HYPERTHERMIA; HYPOTENSION; INFORMATION PROCESSING; INJECTION SITE REACTION; INTERMETHOD COMPARISON; INTERNET; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL SOCIETY; META ANALYSIS; METHODOLOGY; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROPSYCHOLOGY; PALLIDOTOMY; PARKINSON DISEASE; PARKINSONISM; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SUICIDAL BEHAVIOR; SWEAT GLAND DISEASE; SYSTEMATIC REVIEW; THALAMOTOMY; TIME; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE; YAWNING;

AMANTADINE; ANTIPARKINSON AGENTS; APOMORPHINE; BENZOPHENONES; BENZOTHIAZOLES; BROMOCRIPTINE; CATECHOL O-METHYLTRANSFERASE; DEEP BRAIN STIMULATION; DIHYDROERGOCRYPTINE; ERGOLINES; FETAL TISSUE TRANSPLANTATION; GLOBUS PALLIDUS; HUMANS; INDANS; INDOLES; LEVODOPA; LISURIDE; MESENCEPHALON; MONOAMINE OXIDASE INHIBITORS; NEUROSURGICAL PROCEDURES; NITROPHENOLS; PARKINSON DISEASE; PERGOLIDE; PIRIBEDIL; SELEGILINE; THIAZOLES;

EID: 20844444331     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20464     Document Type: Review

References (47)

1. Sacket Dl, Straus S, Richardson S, Rosenber W, Haynes RB, editors. Evidence-based medicine: how to practice and teach EBM. 2nd ed. London: Churchill Livingstone; 2000.
2. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17(Suppl. 4)S1-S166.
3. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
4. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
5. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002;109:1433-1443.
6. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
7. Djaldetti R, Inzelberg R, Giladi N, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 2002; 17:297-302.
8. Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M, FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60.
9. Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomized, placebo-controlled, double-blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74:1071-1079.
10. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002; 105:245-255.
11. Fenelon G, Gimenez-Roldan S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearin-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 2003;110:239-251.
12. Shan DE, Lee SJ, Chao LY, Yeh SI. Gait analysis in advanced Parkinson's disease - effect of levodopa and tolcapone. Can J Neurol Sci 2001;28:70-75.
13. Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001;16:858-866.
14. Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. Parkinsonism Relat Disord 2001;7:107-114.
15. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
16. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
17. Mizuno Y, Yanagisawa N, Kano S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 2003;18:1149-1156.
18. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y, on behalf of the Parkinson's disease research group on the United Kingdom. Ten-year follow-up of three different initial treatments in de-novo PD. A randomized trial. Neurology 2001;57:1687-1694.
19. Montastruc JL, Desboeuf K, Lapeyre-Mestre M, Senard JM, Rascol O, Brefel-Courbon C. Long-term mortality results on the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 2001; 16:511-514.
20. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
21. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial on subcutaneously injected apomorphine for parkinsonian Off-state events. Arch Neurol 2001; 58:1385-1392.
22. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized placebo-controlled study. Mov Disord 2003;18:418-425.
23. Pogarell O, Gasser T, Van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double-blind, placebo-controlled multicentre trial. J Neurol Neurosurg Psychiatry 2002;72:713-720.
24. Wong KS, Lu C-S, Shan D-E, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci 2003;216: 81-87.
25. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, on behalf of the 043 study group. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502.
26. Im JH, Ha JH, Cho IS, Lee MC. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease. A 16-week bromocriptine controlled study. J Neurol 2003;250:90-96.
27. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian movement disorders group. JAMA 2002;287:455-463.
28. Hogl B, Seppi K, Brandauer E, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003; 18:319-323.
29. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18:659-667.
30. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinon disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004;61:97-102.
31. Etminan M, Samii A, Takkouche B, Rochon P. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease. A meta-analysis of randomised controlled trials. Drug Safety 2001;24:863-868.
32. Del Dotto PK Pavese N, Gambaccini G, et al. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001;16: 515-520.
33. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
34. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-238.
35. Vitek JL, Bakay RAE, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 2003;53:558-569.
36. Esselink RAJ, de Bie EMA, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD. Neurology 2004;62:201-207.
37. Gironell A, Kulisevsky J, Rami L. Effects of pallidotomy and bilateral subthalamic stimulation on cognitive function in Parkinson's disease. J Neurol 2003;250:917-923.
38. Green J, McDonald WM, Vitek JL, et al. Neuropsychological and psychiatric sequelae of pallidotomy for PD. Neurology 2002;58: 858-865.
39. Katayama Y, Kasai M, Oshima H, et al. Subthalamic nucleus stimulation for Parkinson's disease: benefits observed in levodopa-intolerant patients. J Neurosurg 2001;95:213-221.
40. Østergaard K, Sunde N, Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 2002;17: 693-700.
41. Funkiewicz A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:834-839.
42. Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002;17:1084-1085.
43. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
44. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons on severe Parkinson's disease. N Engl J Med 2001;344:710-719.
45. Trott CT, Fahn S, Greene P, et al. Cognition following bilateral implants of embryonic dopamine neurons in PD. Neurology 2003; 60:1938-1943.
46. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines from the American Academy of Neurology. Neurology 1988;50(Suppl. 3): S1-S57.
47. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;2:CD003735.